Endothelial Dysfunction Market Size and Growth 2031

The endothelial dysfunction market size is projected to reach US$ 2.94 billion by 2031 from US$ 2.08 billion in 2023. The market is expected to register a CAGR of 4.4% during 2023–2031. Noninvasive methods to assess endothelial dysfunction will likely remain a key trend in the market.

Endothelial Dysfunction Market Analysis

Globally, heart diseases are becoming more prevalent, with developed nations seeing a sharp rise in their incidence. Changes in lifestyle and other health issues are contributing to an increase in the incidences. There is a type of cardiovascular disease among adults in the US. By 2035, it is anticipated that more than 45.1% of Americans will suffer from a cardiovascular illness. This is expected to support the market's expansion throughout the projected period. Players like ZOLL Medical Corp, Sphingo Tec GmbH, Endothelix Inc, SMART Medical Ltd, Perimed AB, Everist Health Inc, Alam Medical SaRI, and Medizinische Messtechnik GmbH are among the key companies in the endothelial dysfunction market. Companies have been implementing strategies that have aided their growth and changed the market differently. The businesses have used both inorganic (like product launches, partnerships, and collaborations) and organic (like launches, expansion, and product approvals) strategies.

Endothelial Dysfunction Market Overview

A change in lifestyle raises the risk of endothelial dysfunction by increasing the incidence of diabetes, hypertension, dyslipidemia, and obesity. Proactive monitoring, early diagnosis, and physical activity can help prevent these. A collection of illnesses known as metabolic syndrome raises the risk of CAD, diabetes, high blood pressure, and other dangerous health issues. The National Heart, Lung, and Blood Institute (NHLBI) published an article on "Metabolic syndrome" that claims that metabolic diseases are common in the United States. That is, the metabolic syndrome affects one in three adult individuals. Already a severe public health issue, type 2 diabetes is becoming more common in children and young adults who are obese. The World Health Organization (WHO) reports that diabetes was a direct cause of 1.5 million deaths in 2019; of these deaths, 48% happened before the age of 70. Diabetes contributed to an additional 460,000 kidney disease-related deaths. Twenty percent of cardiovascular deaths are related to elevated blood sugar. Diabetes ranked as the eighth most common cause of death in the US in 2020, according to the CDC. Compared to adults without diabetes, adults 50 years of age and older with diabetes die 4.6 years earlier, become disabled 6-7 years earlier, and remain disabled for almost 1-2 years longer.

Furthermore, 4.4 million deaths worldwide are attributed to high cholesterol, according to the World Heart Federation. In high- and low-income nations alike, it poses a severe risk for heart disease and stroke. The World Health Organization estimates that 2.6 million deaths in 2022 were related to high cholesterol. As a risk factor for heart disease, high cholesterol is one of the leading causes of disease burden in both developed and developing nations. The rise in diseases like diabetes, obesity, high blood pressure, and cholesterol is primarily attributed to changing modes of transportation, physical immobility from inactivity at work, increased consumption of high-fat and high-sugar foods, and growing urbanization.

Consequently, the endothelial dysfunction market is expanding due to the increasing prevalence of these illnesses. It presents a significant risk for heart disease and stroke in both high- and low-income countries. According to estimates from the World Health Organization, high cholesterol will be a factor in 2.6 million deaths in 2022. High cholesterol is a significant contributor to the burden of disease in both developed and developing countries because it is a risk factor for heart disease. Increased consumption of high-fat and high-sugar foods, growing urbanization, and physical immobility from inactivity at work are all significant contributors to the rise in diseases like diabetes, obesity, high blood pressure, and cholesterol. The market for endothelial dysfunction is growing because of the rising incidence of these diseases.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Endothelial Dysfunction Market: Strategic Insights

Market Size Value in	US$ 1,995.17 million in 2022
Market Size Value by	US$ 2,584.84 million by 2028
Growth rate	CAGR of 4.4% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Endothelial Dysfunction Market Drivers and Opportunities

Increasing Incidence of Cardiovascular Diseases Favors the Market Growth

The Middle East and North Africa's leading cause of death, according to the World Heart Federation, is cardiovascular disease, which claims the lives of 1.4 million people a year or more. Furthermore, over the previous 30 years, there has been a 48% increase in CVD deaths, which have been responsible for 40% and 10% of deaths in Oman and Somalia, respectively. The Middle East and North Africa had age-standardized CVD death rates in 2021 that varied from 134.2 to 600.2 per 100,000 individuals. Thus, the market is driven by the high prevalence of endothelial dysfunction-related cardiovascular diseases.

Rising Usage of Novel Biomarkers and Therapeutic Strategies is Likely to Create Opportunities in the Market

Examining endothelial function can improve risk stratification and early disease detection and assess vascular response to therapeutic interventions. There are studies to understand the pathophysiological mechanisms underlying endothelial dysfunction and atherosclerosis progression in a better way and identify new biomarkers and therapeutic strategies to prevent endothelial dysfunction and atherosclerosis to reduce the risk of developing coronary artery disease (CAD) and related complications. Using liquid biopsies and new molecular biology techniques has enabled the identification of a growing list of molecular and cellular markers of endothelial dysfunction that have provided insight into the molecular basis of atherosclerosis as well as potential biomarkers and therapeutic targets for the prevention and treatment of atherosclerosis and CAD.

Further, therapeutic interventions to increase nitric oxide (NO) bioavailability in the vasculature can improve long-term cardiovascular outcomes in healthy, high-risk patients with advanced atherosclerosis. Current therapeutic strategies focus on enhancing the synthesis or reducing the oxidative inactivation of NO in the human vasculature. Of the available therapeutics, angiotensin-converting enzyme inhibitors and statins have improved endothelial function and cardiovascular outcomes after long-term use. Endothelial dysfunction can also be enhanced through other therapeutic approaches, including targeting NO synthesis through modulation of endothelial nitric oxide synthase (eNOS) coupling, such as folate and tetrahydrobiopterin. Therefore, rising inclination toward using novel biomarkers and growing therapeutic strategies are expected to provide opportunities for the endothelial dysfunction market.

 Endothelial Dysfunction Market Report Segmentation Analysis

Key segments that contributed to the derivation of the endothelial dysfunction market analysis are cause, test type, and end user.

• Based on the cause, the endothelial dysfunction market is divided into hypertension, diabetes, hypercholesterolemia, Bechet’s disease, obesity, and others. The hypertension segment held the most significant market share in 2023.
• By test type, the market is categorized into invasive and noninvasive tests (flow-mediated dilatory, peripheral arterial tonometry (PAT), circulating markers, venous occlusion plethysmography, and others. The invasive tests segment held the largest share of the market in 2023.
• By end user, the market is segmented into hospitals, specialty clinics, ambulatory surgery centers, and others. The hospitals segment held the largest share of the market in 2023.

Endothelial Dysfunction Market Share Analysis by Geography

The geographic scope of the endothelial dysfunction market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

The US, Canada, and Mexico are the three leading nations that were used to analyze North America's endothelial dysfunction market. Rising investments in cardiology informatics and an increase in the prevalence of cardiac diseases are the leading causes of market expansion in the region. Due to factors like the growing prevalence of CAD, an established healthcare system, and research and development efforts aimed at creating cutting-edge endothelial dysfunction medications and devices, the US has the largest endothelial dysfunction market in North America. In the United States, coronary heart disease is the primary cause of death. Since the US has the biggest economy in North America, its population trend significantly impacts any market's growth. The number of Americans 65 and older is predicted to more than double between 2016 and 2026 (from 46 million in 2016 to over 98 million by 2060), making up ~24% of the total population, up from 15%, according to data from the US Bureau of Labor Statistics. The American Heart Association estimates that approximately 6 million adults in the US suffer from heart failure, and that number is expected to rise by 40% by 2035. Approximately half of all adults in the US have some form of cardiovascular disease (CVD). By 2035, it is anticipated that over 130 million adults, or 45.1% of the US population, will suffer from CVD.

Endothelial Dysfunction Market Report Scope

Endothelial Dysfunction Market News and Recent Developments

The endothelial dysfunction market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the endothelial dysfunction market are listed below:

• Perimed has signed an agreement with Lovell Government Services. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the United States. With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf. (Source: Perimed AB, Press Release, April 2023)

Endothelial Dysfunction Market Report Coverage and Deliverables

The “Endothelial Dysfunction Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Endothelial dysfunction market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Endothelial dysfunction market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Endothelial dysfunction market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the endothelial dysfunction market
• Detailed company profiles